Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 884

1.

Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.

Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Shiozaki A, Fujiwara H, Konishi H, Naito Y, Teramukai S, Itoh Y.

Cancer Sci. 2019 Dec;110(12):3754-3760. doi: 10.1111/cas.14218.

2.

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.

Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M.

Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051.

4.

Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.

Ackland SP, Gebski V, Zdenkowski N, Wilson A, Green M, Tees S, Dhillon H, Van Hazel G, Levi J, Simes RJ, Forbes JF, Coates AS; for Breast Cancer Trials Ltd (formerly known as the Australia and New Zealand Breast Cancer Trials Group).

Breast Cancer Res Treat. 2019 Jul;176(2):357-365. doi: 10.1007/s10549-019-05187-y. Epub 2019 Apr 26.

PMID:
31028610
5.
6.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

7.
8.

Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer.

Wang X, He Y, Wang T, Xie Y, Li J, Ouyang T, Fan Z.

Support Care Cancer. 2019 Aug;27(8):3019-3025. doi: 10.1007/s00520-018-4572-8. Epub 2019 Jan 4.

PMID:
30607682
9.

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM.

J Clin Oncol. 2019 Jan 10;37(2):115-124. doi: 10.1200/JCO.18.00419. Epub 2018 Nov 16.

10.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).

Wolff T, Schulz H, Losem C, Reichert D, Hurtz HJ, Sandner R, Harde J, Grebhardt S, Potthoff K, Mueller U, Fietz T.

Eur J Haematol. 2019 Feb;102(2):174-181. doi: 10.1111/ejh.13189. Epub 2018 Nov 23.

PMID:
30347466
11.

The effect of pegylated granulocyte colony-stimulating factor on collateral function and myocardial ischaemia in chronic coronary artery disease: A randomized controlled trial.

Traupe T, Stoller M, Gloekler S, Meier P, Seiler C.

Eur J Clin Invest. 2019 Jan;49(1):e13035. doi: 10.1111/eci.13035. Epub 2018 Nov 6.

PMID:
30316200
12.

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT).

Int J Hematol. 2019 Jan;109(1):107-114. doi: 10.1007/s12185-018-2543-y. Epub 2018 Oct 4. Erratum in: Int J Hematol. 2018 Nov 7;:.

PMID:
30284685
13.

Assessment of Neutrophil Chemotaxis Upon G-CSF Treatment of Healthy Stem Cell Donors and in Allogeneic Transplant Recipients.

Thunström Salzer A, Niemiec MJ, Hosseinzadeh A, Stylianou M, Åström F, Röhm M, Ahlm C, Wahlin A, Ermert D, Urban CF.

Front Immunol. 2018 Sep 11;9:1968. doi: 10.3389/fimmu.2018.01968. eCollection 2018.

14.

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.

Choi C, Yoo BW, Kim CO, Hong T, Jin BH, Seo KS, Jang JY, Park MS.

Drug Des Devel Ther. 2018 Aug 1;12:2381-2387. doi: 10.2147/DDDT.S158277. eCollection 2018.

15.

Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D.

Support Care Cancer. 2019 Apr;27(4):1345-1354. doi: 10.1007/s00520-018-4408-6. Epub 2018 Aug 11.

PMID:
30099602
16.

Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.

Nakov R, Gattu S, Wang J, Velinova M, Schaffar G, Skerjanec A.

Br J Clin Pharmacol. 2018 Dec;84(12):2790-2801. doi: 10.1111/bcp.13731. Epub 2018 Sep 28.

17.

Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.

Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K.

Int J Hematol. 2018 Nov;108(5):524-534. doi: 10.1007/s12185-018-2505-4. Epub 2018 Jul 24. Erratum in: Int J Hematol. 2018 Aug 30;:.

PMID:
30043330
18.

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Oct;109(10):3216-3223. doi: 10.1111/cas.13750.

19.

Filgrastim following HLA-Identical Allogeneic Bone Marrow Transplantation: Long-Term Outcomes of a Randomized Trial.

Ben Othman T, Ghedira H, Ben Abdejlil N, Lakhal A, Torjemane L, Ben Hamed L, Hamida S, Zouari B, Ladeb S.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2459-2465. doi: 10.1016/j.bbmt.2018.07.024. Epub 2018 Jul 21.

20.

Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.

Singh I, Patel A, Patel R, Jose V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):329-337. doi: 10.1007/s00280-018-3620-x. Epub 2018 Jun 15.

PMID:
29948023

Supplemental Content

Loading ...
Support Center